Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 28, 2009

University of Rhode Island Wins $13M Grant to Develop Vaccines for Emerging Infectious Diseases

  • A professor at the University of Rhode Island (URI) has been awarded a $13 million funding from the NIH to develop an integrated gene-to-vaccine program targeting emerging infectious diseases. The aim is to integrate vaccine-design studies in silico with in vitro and in vivo research.

    The NIH money will enable Annie De Groot, M.D., and URI colleagues to collaborate with researchers at Lifespan and EpiVax to develop vaccines that address diseases like heptatitis C and helicobacter pylori as well as engineered bioterror agents.

    “The unique area of focus will be what are called immunome-derived vaccines,” says Dr. De Groot. “Compared to traditional vaccines, immunome-derived vaccines have the potential to be safer and more effective since they focus the protective immune response on the most essential antigenic elements of the pathogenic bacteria or virus while eliminating potentially cross-reactive and deleterious or simply inert components, reducing the potential for adverse outcomes.”

    The funding will also support a training course and pilot grants for researchers interested in using new vaccine-design tools developed by Dr. De Groot’s team. Additionally, the grant will allow Dr. De Groot to hire eight new staff members for the Institute for Immunology and Informatics, and it will also result in new hires at affiliated research centers.


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »